News
CLSD
1.260
+9.57%
0.110
Clearside Biomedical Welcomes Anthony Gibney to Board
TipRanks · 2d ago
CLEARSIDE BIOMEDICAL APPOINTS SEASONED BIOTECHNOLOGY EXECUTIVE ANTHONY S. GIBNEY TO ITS BOARD OF DIRECTORS
Reuters · 2d ago
Press Release: Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors. Appointment Adds Broad Expertise in Business Strategy, Collaborations, Finance, and M&A with Recent Ophthalmic Experience. Anthony Gibney is an experienced biotechnology executive. Clearside is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye.
Dow Jones · 2d ago
Weekly Report: what happened at CLSD last week (0408-0412)?
Weekly Report · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), RxSight (RXST) and Clearside Biomedical (CLSD)
TipRanks · 04/11 09:50
Weekly Report: what happened at CLSD last week (0401-0405)?
Weekly Report · 04/08 09:56
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Clearside Biomedical, Inc. Will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on April 10, 2024. Clearside is revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
Barchart · 04/02 06:05
Weekly Report: what happened at CLSD last week (0325-0329)?
Weekly Report · 04/01 09:56
12 Health Care Stocks Moving In Wednesday's After-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The company's Q4 earnings report came out today. Fresh2 Group stock rose upwards by 5.26% as well.
Benzinga · 03/27 20:31
Weekly Report: what happened at CLSD last week (0318-0322)?
Weekly Report · 03/25 09:57
Clearside Biomedical appoints Chong as CMO
Healthcare Clearside Biomedical appoints Chong as CMO on March 14, 2024. Dr. Victor Chong served most recently as VP, Global Head of Retina DAS at Johnson & Johnson Innovative Medicine. The company is a leader in the field of regenerative medicine.
Seeking Alpha · 03/18 17:56
Weekly Report: what happened at CLSD last week (0311-0315)?
Weekly Report · 03/18 09:56
12 Health Care Stocks Moving In Thursday's Intraday Session
Psyence Biomedical (NASDAQ:PBM) shares rose 52.9% to $1.59 during Thursday's regular session. Aptorum Gr stock moved upwards by 43.65% to $6.22. Mira Pharmaceuticals stock rose by 17.27%.
Benzinga · 03/14 17:31
Clearside Biomedical Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 03/14 11:04
HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Benzinga · 03/14 10:53
Clearside Biomedical: Strong Buy Rating on Robust Financials and Clinical Trial Progress
TipRanks · 03/14 10:27
Navigating a Regulatory Maze: Clearside Biomedical’s Challenge with Global Compliance and Anti-Corruption Laws
TipRanks · 03/14 06:01
Clearside Biomedical Price Target Maintained With a $5.00/Share by JMP Securities
Dow Jones · 03/13 15:33
JMP Securities Reiterates Market Outperform on Clearside Biomedical, Maintains $5 Price Target
Benzinga · 03/13 15:23
Clearside Biomedical Price Target Cut to $4.00/Share From $5.00 by Wedbush
Dow Jones · 03/13 13:41
More
Webull provides a variety of real-time CLSD stock news. You can receive the latest news about Clearside Biomed through multiple platforms. This information may help you make smarter investment decisions.
About CLSD
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.